INAB IN8bio Inc

$INAB In MimiVax's failed trial with newly diagnosed GBM they state: "MimiVax's cancer vaccine missed the primary endpoint of a phase 2 study in patients with newly diagnosed glioblastoma. The New York-based company evaluated the peptide-mimic immunotherapeutic vaccine, called SurVaxM, against placebo in 233 evaluable patients with newly diagnosed brain cancer. SurVaxM was tied to a median overall survival (OS) of 22.8 months compared to 20.3 months for the placebo cohort." IN8bio trial with with newly diagnosed GBM they state: "Overall survival (OS) was equally notable: median OS in repeat-dose patients was 19.5 months, compared to a historical SOC mOS of approximately 14.6 months in this patient population." As an investor in In8bio my concern is the MimiVax latest trial not historical data shows mOS as 20.3 months for placebo. The In8bio showed mOS for their repeat-dose patients of 19.5 months. Looking at these current data it makes In8bio really showing no affect at all to mOS.

$INAB price action near $1 and this low volume are leaving many of us perplexed. It’s been months since management last engaged here on StockTwits, unlike before. Hopefully, the company delivers the important updates they promised for this final quarter of the year, especially regarding potential partnerships. We need some real catalysts now! 🔋🤝